Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar
Ustekinumab Deal – Which Excludes Certain Asian Markets – Is Worth More Than $100m
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
You may also be interested in...
Prestige Biopharma and Intas Pharmaceuticals have announced a commercialization deal for Prestige’s HD204 proposed bevacizumab biosimilar, covering a range of territories including markets in the Americas, Europe, Africa and Asia.
Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.
Hikma told Generics Bulletin earlier this year it was reevaluating the US biosimilars market after witnessing successful launches from several of its rivals. Now the London-based firm has signed an agreement in the US to license and commercialize Bio-Thera Solutions’ Stelara biosimilar candidate.